Compare OXBR & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | ALZN |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Cayman Islands | United States |
| Employees | 3 | N/A |
| Industry | Property-Casualty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.1M |
| IPO Year | N/A | 2021 |
| Metric | OXBR | ALZN |
|---|---|---|
| Price | $0.94 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.00 | ★ $28.00 |
| AVG Volume (30 Days) | 8.8K | ★ 95.7K |
| Earning Date | 04-06-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $497.99 | N/A |
| Revenue Next Year | $42.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $0.51 |
| 52 Week High | $2.85 | $8.22 |
| Indicator | OXBR | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 40.14 |
| Support Level | $0.76 | N/A |
| Resistance Level | $1.46 | $2.59 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 53.57 | 9.28 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer. It provides reinsurance solutions through its subsidiary. It focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. Oxbridge specializes in underwriting medium frequency, high severity risks, where insufficient data exists to analyze effectively the risk/return profile of reinsurance contracts. The company manages its business on the basis of one operating segment, Property and Casualty Reinsurance.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.